BenevolentAI Investor Day Presentation Deck
BenevolentAl's Target ID workflow and tools
Disease
Selection
Target Identification
Prep Phase:
Define disease of
interest and scope
potential assays.
Hyp Gen &
Hyp Val
Assay
Definition
Define the
Tech Approach
Predictions
Hit ID &
Expansion
BenevolentAI TID Tool Portfolio
Triage
Define the Tech Approach, Prediction, and
Assessment
Iteratively formulate a hypothesis for the tools
to predict against, alongside the context used
to define the disease state, then generate
predictions to triage. During triage, scientists
review evidence for each target and determine
progressibility based on relevance to biology.
Discovery
Lead Op
ΤΡΑ
Candidate
Seeking
Assay
Preclinical
Development
Phase I
ΤΡΑ
Assay:
Targets sent to a series of mechanistic and
disease-relevant assays to assess a target's potential.
Target Progressibility Ass sment (TPA)
Assessment on the progressibility potential of the target,
chemistry or biologic opportunity, opportunity to differentiate in
the field, and safety. Can occur before, during, or after targets
are sent to assay.
Phase II
Validation
Package
2. Target ID
Phase III
Portfolio
Entry
Portfolio Entry
Preparation:
Evidence from assays,
surfaced insights, and
analysis combined to
form a validation
package to evaluate
for portfolio entry.
Benevolent 33View entire presentation